Lv4
500 积分 2022-10-07 加入
Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study
14小时前
待确认
Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer
9天前
已完结
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer
13天前
已完结
Datopotamab deruxtecan: rational strategies, novel advancements, challenges, and future perspectives
15天前
已完结
Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial
22天前
已完结
US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer With PIK3CA/ AKT1/ PTEN Alterations
22天前
已完结
US Food and Drug Administration Approval Summary: Trastuzumab Deruxtecan for the Treatment of Adult Patients With Hormone Receptor-Positive, Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2-Low or Human Epidermal Growth Factor Receptor 2-Ultralow Breast Cancer
24天前
已完结
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
27天前
已完结
First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer
28天前
已完结
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
28天前
已完结
皖公网安备34019202002308
